Everi - EVRI Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Everi in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EVRI shares.
View EVRI analyst ratings or view top-rated stocks.

4 brokers have issued 12-month price targets for Everi's shares. Their EVRI share price forecasts range from $24.00 to $35.00. On average, they anticipate the company's stock price to reach $28.75 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price.
View analysts price targets for EVRI or view top-rated stocks among Wall Street analysts.

Everi's stock was trading at $21.35 on January 1st, 2022. Since then, EVRI shares have decreased by 25.6% and is now trading at $15.88.
View the best growth stocks for 2022 here.

Everi saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 2,180,000 shares, a decline of 8.4% from the August 15th total of 2,380,000 shares. Based on an average daily trading volume, of 653,000 shares, the short-interest ratio is currently 3.3 days. Currently, 2.5% of the shares of the stock are short sold.
View Everi's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our EVRI earnings forecast.

Everi Holdings Inc. (NYSE:EVRI) issued its quarterly earnings results on Wednesday, August, 3rd. The credit services provider reported $0.33 EPS for the quarter, meeting analysts' consensus estimates of $0.33. The credit services provider had revenue of $197.22 million for the quarter, compared to the consensus estimate of $182.21 million. Everi had a net margin of 21.84% and a trailing twelve-month return on equity of 73.32%.

75 employees have rated Everi Chief Executive Officer Michael D. Rumbolz on Glassdoor.com. Michael D. Rumbolz has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Everi investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), OrganiGram (OGI), New Residential Investment (NRZ), General Electric (GE), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), Sorrento Therapeutics (SRNE) and Nokia Oyj (NOK).

Everi trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVRI."

Everi's stock is owned by many different institutional and retail investors. Top institutional shareholders include Thrivent Financial for Lutherans (5.77%), Eagle Asset Management Inc. (5.03%), FMR LLC (4.61%), Driehaus Capital Management LLC (2.52%), Emerald Advisers LLC (2.10%) and State Street Corp (2.11%). Insiders that own company stock include Darren Simmons, David Lucchese, Dean A Ehrlich, Eileen F Raney, Geoffrey P Judge, Harper H Ko, Linster W Fox, Mark F Labay, Maureen T Mullarkey, Michael D Rumbolz, Randy L Taylor, Ronald V Congemi and Todd A Valli.
View institutional ownership trends.

Shares of EVRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVRI stock can currently be purchased for approximately $15.88.

Everi (NYSE:EVRI) has a market capitalization of $1.43 billion and generates $660.39 million in revenue each year. The credit services provider earns $152.93 million in net income (profit) each year or $1.59 on an earnings per share basis.

The company employs 1,550 workers across the globe.

Everi's mailing address is 7250 S. Tenaya Way Suite 100, Las Vegas NV, 89113. The official website for the company is www.everi.com. The credit services provider can be reached via phone at (800) 833-7110, via email at evri@jcir.com, or via fax at 866-672-4371.